Sodium Thiosulfate is one of 182 small molecule programs targeting Auditory System Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
121 competitors in Kidney Transplant
Sodium Thiosulfate
Ultomiris
Prevymis
Felzartamab
Biological/vaccine
Cytogam
Zemplar
Cysteine Hydrochloride
Sensipar
Epogen
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Feb 14, 1992
SODIUM THIOSULFATE
NDA NDA020166
Feb 14, 2012
SODIUM THIOSULFATE
NDA NDA203923
Sep 20, 2022
PEDMARK
NDA NDA212937
Sources
Details